231 related articles for article (PubMed ID: 19744744)
1. Inhibition of mesothelin-CA-125 interaction in patients with mesothelioma by the anti-mesothelin monoclonal antibody MORAb-009: Implications for cancer therapy.
Hassan R; Schweizer C; Lu KF; Schuler B; Remaley AT; Weil SC; Pastan I
Lung Cancer; 2010 Jun; 68(3):455-9. PubMed ID: 19744744
[TBL] [Abstract][Full Text] [Related]
2. Phase I clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelin-expressing cancers.
Hassan R; Cohen SJ; Phillips M; Pastan I; Sharon E; Kelly RJ; Schweizer C; Weil S; Laheru D
Clin Cancer Res; 2010 Dec; 16(24):6132-8. PubMed ID: 21037025
[TBL] [Abstract][Full Text] [Related]
3. Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin.
Hassan R; Ebel W; Routhier EL; Patel R; Kline JB; Zhang J; Chao Q; Jacob S; Turchin H; Gibbs L; Phillips MD; Mudali S; Iacobuzio-Donahue C; Jaffee EM; Moreno M; Pastan I; Sass PM; Nicolaides NC; Grasso L
Cancer Immun; 2007 Dec; 7():20. PubMed ID: 18088084
[TBL] [Abstract][Full Text] [Related]
4. Mesothelin targeted cancer immunotherapy.
Hassan R; Ho M
Eur J Cancer; 2008 Jan; 44(1):46-53. PubMed ID: 17945478
[TBL] [Abstract][Full Text] [Related]
5. Mesothelin as a target for chimeric antigen receptor-modified T cells as anticancer therapy.
O'Hara M; Stashwick C; Haas AR; Tanyi JL
Immunotherapy; 2016; 8(4):449-60. PubMed ID: 26973126
[TBL] [Abstract][Full Text] [Related]
6. Recognition of mesothelin by the therapeutic antibody MORAb-009: structural and mechanistic insights.
Ma J; Tang WK; Esser L; Pastan I; Xia D
J Biol Chem; 2012 Sep; 287(40):33123-31. PubMed ID: 22787150
[TBL] [Abstract][Full Text] [Related]
7. Anti-tumor activity of K1-LysPE38QQR, an immunotoxin targeting mesothelin, a cell-surface antigen overexpressed in ovarian cancer and malignant mesothelioma.
Hassan R; Viner JL; Wang QC; Margulies I; Kreitman RJ; Pastan I
J Immunother; 2000; 23(4):473-9. PubMed ID: 10916757
[TBL] [Abstract][Full Text] [Related]
8. Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer.
Hassan R; Remaley AT; Sampson ML; Zhang J; Cox DD; Pingpank J; Alexander R; Willingham M; Pastan I; Onda M
Clin Cancer Res; 2006 Jan; 12(2):447-53. PubMed ID: 16428485
[TBL] [Abstract][Full Text] [Related]
9. Humoral immune response to mesothelin in mesothelioma and ovarian cancer patients.
Ho M; Hassan R; Zhang J; Wang QC; Onda M; Bera T; Pastan I
Clin Cancer Res; 2005 May; 11(10):3814-20. PubMed ID: 15897581
[TBL] [Abstract][Full Text] [Related]
10. Cytotoxic activity of the recombinant anti-mesothelin immunotoxin, SS1(dsFv)PE38, towards tumor cell lines established from ascites of patients with peritoneal mesotheliomas.
Li Q; Verschraegen CF; Mendoza J; Hassan R
Anticancer Res; 2004; 24(3a):1327-35. PubMed ID: 15274292
[TBL] [Abstract][Full Text] [Related]
11. A binding domain on mesothelin for CA125/MUC16.
Kaneko O; Gong L; Zhang J; Hansen JK; Hassan R; Lee B; Ho M
J Biol Chem; 2009 Feb; 284(6):3739-49. PubMed ID: 19075018
[TBL] [Abstract][Full Text] [Related]
12. A live-attenuated Listeria vaccine (ANZ-100) and a live-attenuated Listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: phase I studies of safety and immune induction.
Le DT; Brockstedt DG; Nir-Paz R; Hampl J; Mathur S; Nemunaitis J; Sterman DH; Hassan R; Lutz E; Moyer B; Giedlin M; Louis JL; Sugar EA; Pons A; Cox AL; Levine J; Murphy AL; Illei P; Dubensky TW; Eiden JE; Jaffee EM; Laheru DA
Clin Cancer Res; 2012 Feb; 18(3):858-68. PubMed ID: 22147941
[TBL] [Abstract][Full Text] [Related]
13. Effect of chelator conjugation level and injection dose on tumor and organ uptake of 111In-labeled MORAb-009, an anti-mesothelin antibody.
Shin IS; Lee SM; Kim HS; Yao Z; Regino C; Sato N; Cheng KT; Hassan R; Campo MF; Albone EF; Choyke PL; Pastan I; Paik CH
Nucl Med Biol; 2011 Nov; 38(8):1119-27. PubMed ID: 21741258
[TBL] [Abstract][Full Text] [Related]
14. Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors.
Gubbels JA; Belisle J; Onda M; Rancourt C; Migneault M; Ho M; Bera TK; Connor J; Sathyanarayana BK; Lee B; Pastan I; Patankar MS
Mol Cancer; 2006 Oct; 5(1):50. PubMed ID: 17067392
[TBL] [Abstract][Full Text] [Related]
15. Secretion of N-ERC/mesothelin and expression of C-ERC/mesothelin in human pancreatic ductal carcinoma.
Inami K; Kajino K; Abe M; Hagiwara Y; Maeda M; Suyama M; Watanabe S; Hino O
Oncol Rep; 2008 Dec; 20(6):1375-80. PubMed ID: 19020717
[TBL] [Abstract][Full Text] [Related]
16. Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion.
Rump A; Morikawa Y; Tanaka M; Minami S; Umesaki N; Takeuchi M; Miyajima A
J Biol Chem; 2004 Mar; 279(10):9190-8. PubMed ID: 14676194
[TBL] [Abstract][Full Text] [Related]
17. Phase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1P.
Kreitman RJ; Hassan R; Fitzgerald DJ; Pastan I
Clin Cancer Res; 2009 Aug; 15(16):5274-9. PubMed ID: 19671873
[TBL] [Abstract][Full Text] [Related]
18. The role of mesothelin in tumor progression and targeted therapy.
Tang Z; Qian M; Ho M
Anticancer Agents Med Chem; 2013 Feb; 13(2):276-80. PubMed ID: 22721387
[TBL] [Abstract][Full Text] [Related]
19. Mesothelin-Targeted Thorium-227 Conjugate (MSLN-TTC): Preclinical Evaluation of a New Targeted Alpha Therapy for Mesothelin-Positive Cancers.
Hagemann UB; Ellingsen C; Schuhmacher J; Kristian A; Mobergslien A; Cruciani V; Wickstroem K; Schatz CA; Kneip C; Golfier S; Smeets R; Uran S; Hennekes H; Karlsson J; Bjerke RM; Ryan OB; Mumberg D; Ziegelbauer K; Cuthbertson AS
Clin Cancer Res; 2019 Aug; 25(15):4723-4734. PubMed ID: 31064781
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
